On the eve of the 36th annual J.P. Morgan Healthcare Conference, it’s only fitting to take a look at where pharmaceutical deals ended up at the end of 2017. Suffice to say, at a record low deal volume. Preliminary data show just 96 transactions for pharmaceutical targets were announced last year, the first time pharma […]
Drug companies and managed care organizations are working to keep prices from rising precipitously. Then there’s Pfizer.
There’s been a sharp drop in Pharmaceutical deals in the first quarter of 2017, compared with a year ago. What’s up with that?
AstraZeneca (NYSE: AZN) has been on the receiving end of three different purchases in the first five days of October, selling licenses to three of its non-core assets for a combined upfront payment of $450 million. Its selling spree occurred in tandem with the announced trial failure of its blood thinner Brilinta (ticagrelor), which failed […]
The pharmaceutical industry has largely given up on in-house research and development, saying that the R&D timeline is too costly, long and uncertain to fund with shareholders’ money. The industry has gone from bolt-on acquisitions of smaller companies with marketed products to battling it out for clinical-stage drug candidates. What’s surprised some industry observers is […]
Forget those early- to mid-stage clinical candidates. Pfizer Inc. (NYSE: PFE) jumped the line with its $13.5 billion deal for oncology drug maker Medivation Inc. (NASDAQ: MDVN). The target’s primary product is XTANDI® (enzalutamide), an androgen receptor inhibitor, the leading novel hormone therapy for the treatment of prostate cancer. Pfizer will pay $81.50 per share in […]
This isn’t a sleepy deal. AstraZeneca (NYSE: AZN) sold the ex-U.S. rights to its portfolio of seven established anesthesia medicines to Aspen Global Incorporated. Aspen Global is the holding company for Aspen Group‘s (OTCBB: ASPU) international business that manages and maintains intellectual property rights, and regulatory and commercial strategies of a portfolio of specialist and […]
In August, AbbVie (NYSE: ABBV) paid a record-setting $350 million to United Therapeutics Corp. (NASDAQ: UTHR) for its Rare Pediatric Disease Priority Review Voucher. The fast-track voucher was awarded by the FDA as part of its approval of Unituxin™ (dintuximab), for the treatment of neuroblastoma. On Sept. 8, the FDA cleared Wellstat Therapeutics‘ Xuriden (uridine […]
Valeant Pharmaceuticals International (NYSE: VRX) couldn’t keep its checkbook closed last week. On September 1, Valeant obtained the exclusive license to develop and commercialize brodalumab, a psoriasis drug candidate, from AstraZeneca (NYSE: AZN) for $100 million. Valeant will hold the exclusive rights to develop and commercialize brodalumab globally, except in Japan and certain other Asian countries […]
Last week MedImmune Ltd., the biotech arm of AstraZeneca plc (NYSE: AZN), announced two placements for its investigational compound, MEDI4736. The first announcement was with Juno Therapeutics Inc. (NASDAQ: JUNO), which signed an non-exclusive agreement to test its own investigational CD19-directed chimeric antigen receptor (CAR) T cell candidates with MedImmune’s programmed cell death ligand 1 […]